Ryoko Sekiya

Dr. Ryoko Sekiya

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EKEi Kinai
Ei Kinai
MIMio Ishikura
Mio Ishikura
RMRyui Miyashita
Ryui Miyashita
TYTomoko Yamaguchi
Tomoko Yamaguchi
YCYushi Chikasawa
Yushi Chikasawa
KAKagehiro Amano
Kagehiro Amano
After hepatitis B virus (HBV) infection in people living with HIV (PLWH), various forms of indeterminate serostatuses, including “isolated anti-HBc (IAHBc)”, are observed, but the current interpretation for their HBV immunity seems to be optimistic. This single-center, retrospective cohort study of 1,461 PLWH included individuals with past natural HBV infection and negative history of HBV vaccination. Further, based on their most recent serology status, the selected individuals were classified into either 1) seroconversion, 2) chronic infection, or 3) indeterminate groups. PLWH of the latter group (with indeterminate serostatus) were defined as neither seroconversion [HBsAg(-)/anti-HBs(+)/anti-HBc(+)] nor chronic infection [HBsAg(+)/anti-HBs(-)/anti-HBc(+)]; chronological sub-serostatus of these individuals and clinical interpretations were determined based on long-term serological changes. Of the 878 PLWH with past-HBV infection and no vaccination, seroconversion was documented in 640 (73%), chronic infection in 60 (7%), and 178 (20%) were considered the indeterminate group. Based on a review of 13-year serologic tests (9 test repeats), patients of the indeterminate group were classified as either “isolated anti-HBc (IAHBc)” (n = 118, 66%), “anti-HBs alone” (n = 35, 20%), or “lost anti-HBs/anti-HBc” (n = 25, 14.0%). None showed “resolved infection” pattern. IAHBc was significantly associated with weak HBV immunity, such as viral rebound or non-seroconversion [odds ratio (OR) 2.181, 95% confidence interval (95%CI) (1.064–4.469)], while anti-HBs alone was not [OR: 0.143, 95%CI: 0.041–0.492]. Clinical interpretations of lost anti-HBs/anti-HBc were identical to those of IAHBc. In PLWH, IAHBc and lost anti-HBs/anti-HBc do not indicate resolved but weak/unstable immunity against HBV, whereas anti-HBs alone infers robust immunity.

29 October 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
RSRyoko Sekiya
Ryoko Sekiya
TMTakashi Muramatsu
Takashi Muramatsu
AIAkito Ichiki
Akito Ichiki
YCYushi Chikasawa
Yushi Chikasawa
MBMasato Bingo
Masato Bingo
EKEi Kinai
Ei Kinai
Treatment with tenofovir alafenamide fumarate (TAF) is associated with body weight gain. However, little or no information is available on this issue in Asian populations. This single-center retrospective study included Japanese people living with HIV (PLWH) who satisfied the following criteria; 1) switching from TDF to TAF after HIV-suppression, 2) follow-up for ≥2 years while on TDF and TAF, and 3) no switching of the third antiretroviral agent. Changes in annual body weight and lipid profiles were compared between the TDF and TAF periods. Of 328 patients, dolutegravir (DTG) was used in 118 PLWH. Overall, no significant difference in weight gain was observed between TDF and TAF (0.76 vs. 0.9 kg/year, p = 0.331). In TAF-period, younger (<50 years of age) group showed significantly greater weight gain than older group (1.03 vs. 0.12 kg/year, p = 0.037). In DTG group, weight gain was larger in TAF-period (0.74 vs. 1.31 kg/year, p = 0.046), especially in younger subgroup (1.43 kg/year) compared with older one (-0.12 kg/year). Multivariate regression analysis showed that TAF was not associated with weight gain (estimates 0.201, p = 0.170) except for DTG group, whereas young age was associated with weight gain in all subjects (estimates -0.033/1 year older, p < 0.001), DTG, RAL, and EFV groups. In Japanese PLWH, annual body weight change was comparable in TDF- and TAF-period, while TAF plus DTG correlated with weight gain. Since young age was a key determinant of weight change, careful interpretation is needed for TAF-associated weight gain.

30 September 2026 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
RSRyoko Sekiya
Ryoko Sekiya
TITatsuya Inukai
Tatsuya Inukai
MYMihoko Yotsumoto
Mihoko Yotsumoto
YYYuko Yamada
Yuko Yamada
SKShun Kaneko
Shun Kaneko
SNShigeki Nakamura
Shigeki Nakamura

22 October 2024 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
KIKenichi Ikegaya
Kenichi Ikegaya
TMTakashi Muramatsu
Takashi Muramatsu
RSRyoko Sekiya
Ryoko Sekiya
YSYusuke Sekine
Yusuke Sekine
YHYuko Harada
Yuko Harada
EKEi Kinai
Ei Kinai
Background: The two-drug regimen of dolutegravir/lamivudine (DTG/3TC) is currently an optional antiretroviral therapy (ART). Despite its reported advantages on body weight and lipid profile, the same effects have not yet been reported for Asian population. Methods: We conducted a single-center retrospective study involving Japanese people living with HIV (PLWH). They were divided into four groups: those who had received abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) and continued the same (ABC-ON group) or switched to DTG/3TC (ABC-OFF group), those who had received tenofovir alafenamide fumarate/emtricitabine/dolutegravir (TAF/FTC/DTG) and continued the same (TAF-ON group) or switched to DTG/3TC (TAF-OFF group). We compared changes in viral load, CD4* cell count, CD4*/ CD8* ratio, body weight, BMI, lipid profiles, estimated glomerular filtration rate (eGFR), and fibrosis index based on four factors (FIB4-index) between the pre-switch and post-switch period. Results: Of the 541 PLWH on DTG-based ART, 165, 94, 264 and 18 constituted the ABC-ON, ABC-OFF, TAF-ON, and TAF-OFF groups, respectively. Neither viral rebound nor CD4+decline was observed in the post-switch period in all groups. Multivariate analysis showed significant reduction in total cholesterol, LDL-C and HDL-C in the ABC-OFF group (-6.280,-6.957 and-2.268, p = 0.040, 0.012 and 0.022, respectively), but not in the TAF-OFF group (-3.000, 6.708 and 0.046, p = 0.607, 0.276 and 0.983, respectively). No significant changes were observed in body weight, eGFR, or FIB4-index at 72 weeks after the discontinuation of ABC or TAF. Conclusions: Switching from ABC/3TC/DTG to DTG/3TC lowered lipids significantly, but not with TAF/FTC/ DTG. Neither switch affected body weight or other markers.

9 September 2026 in medRxiv
Verified
Preprint
Open access
PDF file
YTYui Tomo
Yui Tomo
SJSeowoong Jung
Seowoong Jung
YKYuka Kudo-Nagata
Yuka Kudo-Nagata
RSRyoko Sekiya
Ryoko Sekiya
KFKazuaki Fukushima
Kazuaki Fukushima
AKAyu Kasamatsu
Ayu Kasamatsu
Background: Advances in antiretroviral therapy (ART) have transformed human immunodeficiency virus (HIV) infection into a manageable chronic condition. However, people with HIV (PWH) face an increased burden of age-related non-AIDS-defining illnesses. Epigenetic age (EA) and epigenetic age acceleration (EAA), based on DNA methylation, have emerged as objective indicators of biological aging. Although studies in Western countries suggest that EAA levels are elevated in PWH and may decline after ART initiation, evidence in the Japanese population remains scarce. This study aims to characterize EA and EAA in Japanese PWH and to evaluate their associations with the duration of ART, cumulative exposure to specific drug classes, frailty, lifestyle factors, and immunological, metabolic, and inflammatory markers. Methods: This single-center, cross-sectional study involves 100 adult Japanese males with HIV who have received ART for at least 12 months. EA and EAA will be calculated using whole-blood DNA methylation data generated using the Illumina Infinium MethylationEPIC v2.0 BeadChip array and epigenetic clocks developed on Japanese populations. Linear regression models will be used to evaluate the associations between EAA and the factors collected from medical records, laboratory tests, self-administered questionnaires, and comorbidities. Discussion: This study provides baseline data for future longitudinal and comparative studies. The integration of clinical, questionnaire, and omics data facilitates the exploration of biological mechanisms underlying aging in this population. The limitations include the cross-sectional design, which precludes causal inference and the lack of a control group. Graphical

11 October 2026 in HIV Medicine
Verified
Journal Article
Open access
KYKohei Yamashita
Kohei Yamashita
KIKazuhiko Ikeuchi
Kazuhiko Ikeuchi
RSRyoko Sekiya
Ryoko Sekiya
YAYuki Arisato
Yuki Arisato
SMShinya Matsumoto
Shinya Matsumoto
TTTakeya Tsutsumi
Takeya Tsutsumi
Objectives: To compare objectively measured cardiometabolic health between people living with HIV (PLWH) and individuals without HIV using nationwide health checkup data linked to administrative claims, thereby partially mitigating surveillance bias associated with routine HIV care. Methods: We conducted a cross‐sectional matched analysis using the JMDC database, which links administrative claims with annual health checkup data. Men with HIV receiving antiretroviral therapy (ART) and men without HIV who underwent health checkups between 2017 and 2023 were included. PLWH were exact‐matched 1:5 to individuals without HIV by age and calendar year. Cardiometabolic outcomes included hypertension, diabetes mellitus, dyslipidaemia and BMI, defined using treatment information and objectively measured clinical parameters. Conditional logistic regression and matched‐set fixed‐effects linear regression were used. Results: We included 2596 PLWH and 12 980 matched individuals without HIV (median age 45.0 years [IQR 37.0–51.0]). PLWH were more likely to receive treatment for hypertension, diabetes mellitus and dyslipidaemia, whereas measured systolic blood pressure, HbA1c and LDL‐C were comparable to or lower than those in individuals without HIV. HIV infection was not independently associated with hypertension (aOR 0.95, 95% CI 0.82–1.09) or diabetes mellitus (aOR 1.00, 0.82–1.22) but was associated with dyslipidaemia (aOR 1.22, 1.08–1.39) and slightly higher BMI (adjusted mean difference 0.28 kg/m 2 , 0.02–0.55). Conclusions: Among men receiving contemporary HIV care in Japan, HIV infection was associated with modest differences in BMI and dyslipidaemia but not with hypertension or diabetes mellitus.